Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients

Bibhuti Das, Vivian Dimas, Kristine Guleserian, Chantale Lacelle, Kristin Anton, Lindy Moore, Robert Morrow

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

Original languageEnglish (US)
Article numbere12844
JournalPediatric Transplantation
Volume21
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Pediatrics
Antilymphocyte Serum
Recovery of Function
Methylprednisolone
Graft Rejection
Heart Transplantation
Therapeutics
Immunoglobulin G
Morbidity
Survival
Mortality
Antibodies
alemtuzumab
Transplant Recipients
Rituximab

Keywords

  • alemtuzumab (Campath-1H)
  • pediatric heart transplant
  • refractory acute rejections

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients. / Das, Bibhuti; Dimas, Vivian; Guleserian, Kristine; Lacelle, Chantale; Anton, Kristin; Moore, Lindy; Morrow, Robert.

In: Pediatric Transplantation, Vol. 21, No. 1, e12844, 01.02.2017.

Research output: Contribution to journalArticle

@article{b2c35b3bff4d48bbaf7d205407669c08,
title = "Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients",
abstract = "Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22{\%}±5{\%} to 33{\%}±5{\%} (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.",
keywords = "alemtuzumab (Campath-1H), pediatric heart transplant, refractory acute rejections",
author = "Bibhuti Das and Vivian Dimas and Kristine Guleserian and Chantale Lacelle and Kristin Anton and Lindy Moore and Robert Morrow",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/petr.12844",
language = "English (US)",
volume = "21",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients

AU - Das, Bibhuti

AU - Dimas, Vivian

AU - Guleserian, Kristine

AU - Lacelle, Chantale

AU - Anton, Kristin

AU - Moore, Lindy

AU - Morrow, Robert

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

AB - Despite substantial improvements in survival after pediatric heart transplantation, refractory rejection remains a major cause of morbidity and mortality. We have utilized ALE (Campath-1H) in six consecutive patients with refractory rejection. These rejection episodes persisted despite conventional treatment, which included intravenous methylprednisolone, rituximab, immunoglobulin G, and antithymocyte globulin. In our series, after ALE therapy, LV SF increased from 22%±5% to 33%±5% (P=.01). However, in our series, ALE therapy neither led to persistent LV function recovery nor could it prevent subsequent antibody-mediated rejection.

KW - alemtuzumab (Campath-1H)

KW - pediatric heart transplant

KW - refractory acute rejections

UR - http://www.scopus.com/inward/record.url?scp=85006022177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006022177&partnerID=8YFLogxK

U2 - 10.1111/petr.12844

DO - 10.1111/petr.12844

M3 - Article

C2 - 27862703

AN - SCOPUS:85006022177

VL - 21

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 1

M1 - e12844

ER -